Listing 3 - Actual negotiations

Indication:

Severe malaria

Indication:

Treatment of hyperargininemia in adults and pediatric patients aged 2 years and older with arginase 1 deficiency, in conjunction with dietary protein restriction

Indication:

​For post-transplant maintenance for measurable residual disease (MRD) positive FLT3-ITD mutated acute myeloid leukemia (AML).

Indication:

Actinic keratosis

Indication:

For once-weekly administration for chronic weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity, in adults with an initial body mass index of: 30 kg/m2 or greater (obesity), or 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, prediabetes, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease).

Indication:

For the treatment of adults with acquired thrombotic thrombocytopenic purpura in combination with plasma exchange and immunosuppressive therapy

Indication:

For the treatment of adult patients with C3 glomerulopathy (C3G) to reduce proteinuria

Indication:

For the treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy or primary immune-complex membranoproliferative lomerulonephritis to reduce proteinuria.

Indication:

For the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids, or who have experienced a relapse during corticosteroid taper.

Indication:

For the treatment of patients with a clinical diagnosis of mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (early Alzheimer's disease) who are apolipoprotein E ε4 (ApoE4) noncarriers or heterozygotes, and who have confirmed amyloid pathology.